Respiratory Models

Aragen combines years of experience in the development of respiratory disease therapeutics with the latest tools and assays to help you accelerate your biotherapeutic or small molecule drug development.  Our validated rodent models enable clients to evaluate the potential efficacy of novel asthma, anti-inflammatory, anti-fibrotic and bronchodilator agents targeting lung fibrosis.

Asthma is a common disease of the lungs. It is estimated that more than 22 million Americans have asthma, and it is one of the most common chronic diseases of childhood. Aragen’s state of the art analysis tools include:

Whole Body Plethysmograph (WBP)

  • Airway hyper responsiveness,
  • Respiratory rate
  • PenH

FlexiVent Lung Functional Analysis

  • Resistance
  • Compliance
  • Elastance

Abbott iSTAT

  • Blood glass measurement to monitor Hypoxia -related symptoms

PAS (periodic-acid-Schiff) Staining

  • Detection of structures that contain high concentrations of carbohydrate macromolecules (eg. glycogen, glycoprotein, proteoglycan) typically found in mucus.

Serum and Bronchoalveolar Lavage Fluid Analysis

  • Antigen-specific IgE and IgA levels
  • Cytokines levels

Our rodent asthma models include induction by ova or other allergens (cedar pollen, dust mote antigen). Models can range from mild- to severe disease in order to evaluate a range of treatment options.

RSV infection is the major cause of severe respiratory illness in infants and young children, as well as immune-compromised individuals and the elderly. It causes a range of illnesses varying from mild infection to life-threatening bronchiolitis and respiratory failure. Rodent models for testing efficacy and safety in preclinical studies provide a critical component to the development of anti-RSV antibodies, small molecules and vaccines. Visit our RSV page for details.

The combination of lipopolysaccharide (LPS)/Zymosan-induced lung injury is a very useful experimental in vivo model with end results of microvascular injury, edema and diffuse alveolar damage with intrapulmonary hemorrhage, which are the characteristics in patients with ALI/ARDS. When delivered into animals, LPS/Zymosan exposure display major features of microvascular lung injury, including leukocyte accumulation in lung tissue, pulmonary edema, profound lung inflammation and mortality.  Aragen has developed a well characterized ALI model induced by combined administration of LPS and Zymosan, with detailed end results of bronchoalveolar lavage infiltrate, cytokine analysis, hypoxia measurements and histology with capability of lung function analysis. Download our Acute Lung Injury Technical Aid below.

As the most commonly used model for IPF, Bleomycin induction causes inflammatory and fibrotic reactions in rodent lungs within a short period of time and successfully replicates many of the pathological characteristics, including abnormal deposition and accumulation of collagen in lung tissue, associated with IPF. Download our technical collateral below for more details.

This rodent model, induced by the administration of crystalline silico dioxide (or silica) displays many pathophysiological features of chronic inflammation and pulmonary fibrosis, which can be used as an experimental model for IPF and silicosis. Download our technical collateral below for more details.

Respiratory Disease Flyer

White Paper

Respiratory Models Technical Summary

Acute Lung Injury Technical Aid